Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520
Tweet Send to a Friend
Roth Capital analyst Joseph Pantginis trimmed his price target on Regeneron Pharma (NASDAQ: REGN) to $520.00 (from $555.00) but ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
